Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

German researchers focus on Na+/H+-exchange inhibitors

Feb. 10, 1997

Chymase inhibitors from Green Cross

Feb. 7, 1997

First Corlopam Renal Program study completed

Feb. 6, 1997

Cell migration inhibitors from Teijin

Feb. 6, 1997

Nortran completes trials in volunteers with antiarrhythmic

Feb. 5, 1997

Tanabe synthesizes ET antagonists

Feb. 5, 1997

AHP claims smooth muscle cell proliferation inhibitors

Feb. 4, 1997

Mylan Laboratories receives FDA approval for generic formulation

Jan. 30, 1997

FDA Cardiovascular and Renal Drugs Advisory Committee to meet February 27-28

Jan. 29, 1997

New use for established antianginal agent

Jan. 29, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.